Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  ISIS Pharmaceuticals, Inc.    ISIS

Financials ($)
Sales 2016 239 M
EBIT 2016 -148 M
Net income 2016 -166 M
Finance 2016 125 M
Yield 2016 -
Sales 2017 293 M
EBIT 2017 -142 M
Net income 2017 -147 M
Finance 2017 127 M
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017
EV / Sales 2016 20,2x
EV / Sales 2017 16,5x
Capitalization 4 946 M
More Financials
Ionis Pharmaceuticals, Inc. engages in the development and commercialization of antisense drug discovery.It operates through two segments: Drug Discovery & Development Operations and Akcea.The Drug Discovery & Development Operations segment provides drugs to treat a variety of health conditions,... 
More about the company
Surperformance© ratings of ISIS Pharmaceuticals, Inc.
Trading Rating : Investor Rating :
More Ratings
04/22 WEBCAST ALERT : Ionis Pharmaceuticals' First Quarter 2016 Financial Results Conf..
04/21 IONIS PHARMACEUTICALS : Highlights Antisense Drugs to Treat Neurological Disease..
04/20 IONIS PHARMACEUTICALS : Reports Data Update from Nusinersen Phase 2 Study in Inf..
04/15 ISIS PHARMACEUTICALS : Ionis Pharmaceuticals Highlights Antisense Drugs to Treat..
04/13 IONIS PHARMACEUTICALS : Mizuho Trust & Banking Co. Ltd. Invests $10,501,000 in I..
04/07DJIonis Shares Tumble After FDA Halts Co-Developer's Study
04/07 IONIS PHARMACEUTICALS : Advances Nusinersen in the Ongoing SHINE Study in Patien..
04/07 IONIS PHARMACEUTICALS : Provides Update on IONIS-TTRRX Program
More news
Sector news : Biotechnology & Medical Research - NEC
02:19p BRIEF : Sanofi girds for another fight
04/29 SANOFI : offers to buy Medivation for $9.3bn
04/29 SANOFI : France's Sanofi makes $9.3 billion bid for US cancer drug giant
More sector news : Biotechnology & Medical Research - NEC
4-Traders Strategies on ISIS PHARMACEUTICALS, INC. 
2014A resistance as obstacle
More Strategies
News from SeekingAlpha
2015 Game Plan For The Week - Cramer's Mad Money (12/18/15)
2015 PREMARKET BIOTECH DIGEST : Portola's Milestone, Shkreli Resigns, BioMarin DMD Dr..
2015 Isis Pharma has had enough, name changed to Ionis Pharmaceuticals
2015 Bear Afoot? No Recession Needed For A Possible Sighting
2015 PREMARKET BIOTECH DIGEST : Gilead's Upside, Shire-Baxalta Deal, ARIAD Lowers Gui..
Duration : Period :
ISIS Pharmaceuticals, Inc. Technical Analysis Chart | ISIS | US4643301090 | 4-Traders
Full-screen chart
Technical analysis trends ISIS PHARMACEUTIC...
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions